Latest Warrants News

Brightstar Resources reports compelling new gold assay results from its Sandstone Hub drilling, highlighting significant mineralisation at the Bull Oak deposit and promising early-stage findings at Sandstone North.

APA Group has announced an estimated ordinary dividend of AUD 0.30 per unit for the first half of 2025, accompanied by a Dividend Reinvestment Plan offering a 1.5% discount and currency payment choices.

Kula Gold reports standout high-grade gold intercepts up to 31.3 grams per tonne from ongoing drilling at its Mt Palmer project, advancing the asset toward a potential resource estimate.

Shift4 Payments, LLC has entered into a definitive scheme implementation agreement to acquire Smartpay Holdings Limited at NZ$1.20 per share, subject to regulatory and shareholder approvals. The transaction outlines a detailed timetable and conditions, including Overseas Investment Office consent and court sanction.

Growthpoint Properties Australia has announced a final distribution of 9.1 cents per security for FY25, maintaining its full-year guidance and sustainability commitments.

Cosmo Metals has revealed significant new gold lode extensions at its Nundle Goldfield project in NSW, following interpretation of preliminary LiDAR survey data. The findings highlight underexplored potential in historic mining areas, setting the stage for targeted drilling.

Askari Metals is advancing its African exploration strategy with detailed field campaigns targeting tin, tantalum, and gold mineralisation in Namibia and Ethiopia, while evaluating strategic acquisitions to bolster its portfolio.

Trading in Alphinity Global Equity Fund's Active ETF (XALG) has been temporarily halted, with personal trading also paused pending further announcements.

Recce Pharmaceuticals has locked in a non-dilutive A$30 million debt facility with Avenue Capital Group, extending its cash runway to support pivotal Phase 3 trials and commercialisation of its synthetic anti-infective R327G.

AMP Limited has announced a quarterly distribution of AUD 1.9069 per AMP Capital Notes 2 security, payable in September 2025, reflecting a total annualised yield of 7.57%.

Amplia Therapeutics has reported a rare pathological complete response in a patient from its ACCENT trial, highlighting promising potential for its drug narmafotinib in treating advanced pancreatic cancer.

New World Resources has successfully completed a placement of 32 million shares at $0.02 each to its board and senior management, following shareholder approval. This move subtly reshapes the company’s capital structure ahead of its copper and base metals projects in the US.